ChromaDex (NASDAQ: CDXC) reported Q1 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $13.76 million.

“We had a strong first quarter with total net sales of $14.3 million and further global expansion,” says ChromaDex CEO Rob Fried. “We made swift, targeted adjustments to the business, streamlining costs, updating marketing messages, and prioritizing scientific research focused on viral stress on immune response at the cellular level.”

For earnings history and earnings-related data on ChromaDex (CDXC) click here.